-
Mashup Score: 0The Texas MPN Workshop - 4 year(s) ago
Discover the Texas MPN Workshop! Watch the presentations on-demand featuring experts such as Ruben Mesa, Claire Harrison, Srdan Verstovsek and Naveen Pemmaraju.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Virtual Medical Meetings Open Up Online Communication for Myeloproliferative Neoplasms - 4 year(s) ago
In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed recent advances for the treatment of patients with MPNs and shared his thoughts on recent hematologic meetings and the growing role of social media during the COVID-19 pandemic.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 13Updates on ropeginterferon in PV - 4 year(s) ago
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the results of PROUD-PV (NCT01949805) and CONTINUATION-PV…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives his thoughts on classifying myeloproliferative neoplasms (MPNs)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
International interactive virtual workshop on the biology and therapy of Myeloproliferative Neoplasms co-led by Dr. Ruben Mesa (Mays Cancer Center at UT
Source: SymplurCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape - 4 year(s) ago
Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Treating Asymptomatic Patients With Polycythemia Vera - 4 year(s) ago
Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The 1st Texas MPN Workshop brought together a world-leading faculty to discuss the latest hot topics in myeloproliferative neoplasms. View the discussions on-demand here: 👉https://t.co/6QPh5Uyupp👈 #MPNsm #OncoAlert @OncoAlert #TxMPN2020 #HemOnc https://t.co/XLebMbufoz